Trial Profile
Nintedanib as Maintenance Treatment of Pleural Malignant Mesothelioma (NEMO): a Randomized Double Blinded Phase II Study of the EORTC Lung Cancer Group
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 09 Apr 2024
Price :
$35
*
At a glance
- Drugs Nintedanib (Primary)
- Indications Malignant-mesothelioma
- Focus Therapeutic Use
- Acronyms NEMO
- 12 Jan 2024 This trial has been completed in Belgium according to European Clinical Trials Database record.
- 06 Sep 2023 Planned End Date changed from 31 Dec 2022 to 31 Mar 2024.
- 06 Sep 2023 Planned primary completion date changed from 31 Dec 2022 to 31 Dec 2023.